Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DN48GC
|
|||
| Drug Name |
DNL919
|
|||
| Synonyms |
TAK-920
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 1 | [1] | |
| Company |
TAKEDA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Triggering receptor expressed on monocytes 2 (TREM2) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05450549) A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Denali | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.